We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Symptomatic Hepatocellular Liver Injury With Hyperbilirubinemia in Two Patients Treated With Rivaroxaban.
- Authors
Liakoni, Evangelia; Rätz Bravo, Alexandra E.; Terracciano, Luigi; Heim, Markus; Krahenbühl, Stephan
- Abstract
IMPORTANCE Treatment with the new oral anticoagulant rivaroxaban can be associated with severe liver injury. OBSERVATIONS We report 2 patients with predominantly hepatocellular liver injury that had onset during treatment with rivaroxaban. Both were symptomatic, had massively elevated transaminase activity levels and hyperbilirubinemia, and fulfilled the criteria of Hy's law. Liver biopsy in 1 patient revealed centroacinar hepatocyte necrosis as the predominant finding. Both patients showed a rapid biochemical and clinical recovery after discontinuing rivaroxaban therapy. Between 2008 and 2013, 42 cases of liver injury possibly associated with rivaroxaban treatment have been reported to the Swiss Agency of Therapeutic Products (Swissmedic). Thirteen of these patients fulfilled the criteria of Hy's law. CONCLUSIONS AND RELEVANCE Treatment with rivaroxaban can be associated with severe, symptomatic liver injury. Physicians should be aware of this adverse drug reaction. We propose rapid discontinuation of treatment with rivaroxaban in case of symptomatic liver injury and, taking into account its severity, avoiding reexposure.
- Publication
JAMA Internal Medicine, 2014, Vol 174, Issue 10, p1683
- ISSN
2168-6106
- Publication type
Article
- DOI
10.1001/jamainternmed.2014.3912